Pharmacokinetics of linagliptin in subjects with hepatic impairment.

ABSTRACT:

What is already known about this subject

• Linagliptin is an oral, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved in the United States, Europe and elsewhere in 2011 for the treatment of type 2 diabetes mellitus. • The elimination of linagliptin is primarily non-renal. Therefore, a potential effect of hepatic impairment on the elimination of linagliptin may have important implications for dosing recommendations.

What this study adds

• This study shows that mild, moderate or severe hepatic impairment did not result in an increase in linagliptin exposure after single and multiple dosing as compared with normal hepatic function. • No linagliptin dose adjustment is required in patients with any degree of hepatic impairment.

Aim

To investigate w

SUBMITTER: Graefe-Mody U 

PROVIDER: S-EPMC3394131 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature